RiceBran Technologies (RIBT) 10-Q 12 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 05, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	RiceBran Technologies
Entity Central Index Key	1,063,537
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,927,204
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Consolidated Statements of Operations (Unaudited) [Abstract]
Revenues	$ 11,435	$ 10,051
Cost of goods sold	8,924	7,814
Gross profit	2,511	2,237
Operating expenses:
Selling, general and administrative	2,913	3,379
Depreciation and amortization	114	348
Total operating expenses	3,027	3,727
Loss from operations	(516)	(1,490)
Other income (expense):
Interest income	3	33
Interest expense - accreted on debt	(542)	(292)
Interest expense - other	(864)	(799)
Change in fair value of derivative warrant liabilities	1,099	811
Gain on resolution of Irgovel purchase litigation	0	1,598
Foreign currency exchange, net	19	66
Loss on extinguishment of debt	(1,680)	0
Other expense, net	(120)	(65)
Total other income (expense)	(2,085)	1,352
Loss before income taxes	(2,601)	(138)
Income tax benefit	0	0
Net loss	(2,601)	(138)
Net loss attributable to noncontrolling interest in Nutra SA	319	438
Net loss attributable to RiceBran Technologies shareholders	(2,282)	300
Dividend on preferred stock - beneficial conversion feature	(778)	(551)
Net loss attributable to RiceBran Technologies common shareholders	$ (3,060)	$ (251)
Loss per share attributable to RiceBran Technologies common shareholders
Basic (in dollars per share)	$ (0.32)	$ (0.03)
Diluted (in dollars per share)	$ (0.32)	$ (0.03)
Weighted average number of shares outstanding
Basic (in shares)	9,657,543	9,215,684
Diluted (in shares)	9,657,543	9,215,684

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Consolidated Statements of Comprehensive Loss [Abstract]
Net loss	$ (2,601)	$ (138)
Other comprehensive (loss) income - foreign currency translation, net of tax	145	446
Comprehensive (loss) income, net of tax	(2,456)	308
Comprehensive loss attributable to noncontrolling interest, net of tax	268	293
Total comprehensive (loss) income attributable to RiceBran Technologies shareholders	$ (2,188)	$ 601

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,366	$ 451
Accounts receivable, net of allowance for doubtful accounts of $497 and $491, respectively (variable interest entity restricted $618 and $398, respectively)	2,944	2,085
Inventories	4,028	3,773
Operating taxes recoverable	8	6
Deposits and other current assets	896	1,213
Total current assets	11,242	7,528
Property and equipment, net (variable interest entity restricted $2,599 and $2,481, respectively)	18,881	18,933
Goodwill	790	790
Intangible assets, net	206	242
Operating taxes recoverable	1,203	1,241
Other long-term assets	141	111
Total assets	32,463	28,845
Current liabilities:
Accounts payable	3,341	3,710
Accrued salary, wages and benefits	3,824	3,828
Accrued expenses	3,921	3,945
Current maturities of long-term debt (variable interest entity nonrecourse $7,399 and $6,816, respectively)	7,435	9,878
Total current liabilities	18,521	21,361
Long-term debt, less current portion (variable interest entity nonrecourse $0 and $0, respectively)	5,568	6,009
Derivative warrant liabilities	494	1,527
Deferred tax liability	29	29
Total liabilities	24,612	28,926
Commitments and contingencies
Temporary Equity
Preferred stock, Series F, convertible, 20,000,000 shares authorized, 3,000 convertible shares issued and outstanding	0	551
Total temporary equity	0	551
Equity (Deficit) attributable to RiceBran Technologies shareholders:
Common stock, no par value, 50,000,000 shares authorized, 10,927,204 and 10,790,351 shares issued and outstanding	273,853	264,232
Accumulated deficit	(262,879)	(259,819)
Accumulated deficit attributable to noncontrolling interest in Nutra SA	(416)	(699)
Accumulated other comprehensive loss	(4,252)	(4,346)
Total equity (deficit) attributable to RiceBran Technologies shareholders	7,851	(632)
Total liabilities, temporary equity and equity (deficit)	32,463	28,845
Series F Convertible Preferred Stock [Member]
Equity (Deficit) attributable to RiceBran Technologies shareholders:
Preferred stock	551	0
Series G Convertible Preferred Stock [Member]
Equity (Deficit) attributable to RiceBran Technologies shareholders:
Preferred stock	$ 994	$ 0

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 497	$ 491
Current liabilities:
Current portion of long-term debt (nonrecourse)	7,435	9,878
Long-term liabilities:
Long-term debt, less current portion (nonrecourse)	$ 5,568	$ 6,009
(Deficit) Equity attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	20,000,000
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	50,000,000	25,000,000
Common stock, shares issued (in shares)	10,927,204	10,790,351
Common stock, shares outstanding (in shares)	10,927,204	10,790,351
Variable Interest Entity [Member]
Current assets:
Accounts receivable, variable interest entity restricted	$ 618	$ 398
Variable interest entity restricted portion of property and equipment, net	2,599	2,481
Current liabilities:
Current portion of long-term debt (nonrecourse)	7,399	6,816
Long-term liabilities:
Long-term debt, less current portion (nonrecourse)	$ 0	$ 0
Series F Convertible Preferred Stock [Member]
Temporary Equity
Preferred stock, shares authorized (in shares)		20,000,000
Convertible preferred stock, shares issued (in shares)		3,000
Convertible preferred stock, shares outstanding (in shares)		3,000
(Deficit) Equity attributable to RiceBran Technologies shareholders:
Convertible preferred stock, shares issued (in shares)	3,000
Convertible preferred stock, shares outstanding (in shares)	3,000
Series G Convertible Preferred Stock [Member]
(Deficit) Equity attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	3,000
Convertible preferred stock, shares issued (in shares)	2,000
Convertible preferred stock, shares outstanding (in shares)	2,000

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flow from operating activities:
Net loss	$ (2,601)	$ (138)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	583	721
Stock and share-based compensation	293	243
Change in fair value of derivative warrant liabilities	(1,099)	(811)
Loss on extinguishment of debt	1,680	0
Gain on resolution of Irgovel purchase litigation	0	(1,598)
Interest accreted	559	292
Other	29	37
Changes in operating assets and liabilities:
Accounts receivable	(874)	(507)
Inventories	(217)	(354)
Accounts payable and accrued expenses	(625)	78
Other	383	(9)
Net cash used in operating activities	(1,889)	(2,046)
Cash flows from investing activities:
Change in restricted cash	0	1,921
Purchases of property and equipment	(132)	(208)
Net cash provided by (used in) investing activities	(132)	1,713
Cash flows from financing activities:
Payments of debt	(8,644)	(10,329)
Proceeds from issuance of debt, net of issuance costs	5,624	9,088
Proceeds from issuance of debt and warrants, net of issuance costs	5,518	300
Proceeds from issuance of preferred stock and warrants, net of issuance costs	1,747	2,554
Proceeds from sale of membership interests in Nutra SA	550	0
Net cash provided by financing activities	4,795	1,613
Effect of exchange rate changes on cash and cash equivalents	141	(24)
Net change in cash and cash equivalents	2,915	1,256
Cash and cash equivalents, beginning of period	451	1,070
Cash and cash equivalents, end of period	3,366	2,326
Supplemental disclosures:
Cash paid for interest	672	492
Cash paid for income taxes	0	0
Subordinated note exchanged fro Series G Preferred Stock	$ 138	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2017
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2016. The report of our independent registered public accounting firm that accompanies the audited consolidated financial statements for the year ended December 31, 2016, included in that Annual Report on Form 10-K, contains a going concern explanatory paragraph in which our independent registered public accounting firm expressed substantial doubt about our ability to continue as a going concern. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared assuming we will continue as a going concern based on the realization of assets and the satisfaction of liabilities in the normal course of business. Recent Accounting Standards Recent accounting standards not yet adopted In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and International Financial Reporting Standards. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. An entity may choose to adopt the new standard either retrospectively or through a cumulative effect adjustment as of the start of the first period for which it applies the new standard. The guidance is effective for our annual and interim periods beginning in 2018, however, early adoption is permitted. We have begun to evaluate the impact that adoption of this guidance will have on our consolidated financial statements but have not completed the evaluation and implementation process. We have not yet selected a transition method but have determined that we will utilize the deferred effective date of January 1, 2018, to adopt the standard. In February 2016, the FASB issued guidance which changes the accounting for leases. Under prior GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on the lease’s classification as a finance or operating lease. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest expense on the lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard. In June 2016, the FASB issued a new credit loss standard that replaces the incurred loss impairment methodology in current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It is effective for annual reporting periods beginning after December 15, 2019 and interim periods within those annual periods. Early adoption for fiscal years beginning after December 15, 2018 is permitted. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first effective reporting period. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard Recently adopted accounting standards In January 2017, the FASB issued a new goodwill impairment standard that simplifies the goodwill impairment testing methodology. The new standard eliminates Step 2 of the goodwill impairment test, in which an entity determines the fair value at the test date of its assets and liabilities using the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. It is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We adopted the standard as of January 1, 2017, with no effect on our financial position or results of operations. In March 2016, the FASB issued new guidance that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The guidance also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. The guidance is effective for our annual and interim periods beginning in 2017 with early adoption permitted. We adopted the standard in the first quarter of 2017 and changed our accounting policy to recognize forfeitures as they occur. This change did not have a material effect on our results of operations as we previously did not apply an estimated forfeiture rate to restricted stock awards to our officers and directors. Additionally, most of our outstanding stock option awards vest on a monthly basis over the vesting period (generally three or four years). As these awards do not have performance conditions, the expense is recognized each month on a straight-line basis and excludes the effect of the estimated forfeiture rate as there was no risk of expensing awards that would be subsequently forfeited prior to vesting.

LIQUIDITY, GOING CONCERN AND MA

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN	3 Months Ended
	Mar. 31, 2017
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN [Abstract]
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN	NOTE 2. LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLAN We have improved our USA segment cash position since December 31, 2016 as a result of completing a debt and equity raise in February. The Brazil segment continues to be a challenging operating unit although it has improved. On a consolidated basis, we continued to experience losses and negative cash flows from operations which raises substantial doubt about our ability to continue as a going concern for a period of one year from the issue date of these financial statements. In February 2017, as discussed further in Note 7, we received net proceeds of $7.2 million from the sale and issuance of preferred stock, senior debentures and related warrants. The net proceeds were used in part to pay in full amounts owing our previous senior lender ($3.8 million) and to pay principal and accrued interest on our subordinated notes ($0.5 million). In addition, we lowered the interest rate and extended the maturity date of our subordinated notes. Consequently, we believe the Corporate and USA segments are adequately funded at this time to allow us to operate and execute on our business strategy for achieving consistent and positive operational cash flows in the USA segment. We continue to believe that we will be able to obtain additional funds to operate our business, should it be necessary; however, there can be no assurances that our efforts will prove successful. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. The Brazil segment consists of the consolidated operations of Nutra SA, LLC (Nutra SA), whose only operating subsidiary is Industria Riograndens De Oleos Vegetais Ltda. (Irgovel), located in Pelotas, Brazil. Irgovel completed the final stages of a major capital expansion during the first quarter of 2015. Throughout 2014, significant cash was used during the shutdown period and subsequent restart of the plant. In 2016, we invested $1.1 million in Nutra SA to fund completion of the capital project and Irgovel working capital needs. Under the terms of the February 2017 Transactions, we are prohibited from contributing additional funding to Irgovel. Beginning in the second quarter of 2016 and through the fourth quarter of 2016, the Brazil segment experienced severe cash shortages resulting in an increase in accounts payable (principally to raw bran suppliers) and accrued payroll related tax obligations as we delayed non-essential payments. The nonpayment of working capital liabilities resulted in suppliers refusing to ship raw bran and other materials necessary to maintain steady operation of the plant. In addition to the Brazil segment working capital issues, the funds necessary to meet scheduled debt payments no longer existed without additional equity funding. As a result, the Brazil segment ceased making all bank debt payments in the second and third quarters of 2016. Discussions have ensued with the related banks with regard to renegotiation of existing debt agreements. However, there is no assurance these discussions will be successful. In 2016, our minority partners (the Investors) contributed $1.7 million to Irgovel and an additional $0.7 million through April of 2017. With this equity support, Irgovel management has negotiated various raw bran supply agreements that management believes will allow Irgovel to obtain rice bran on a consistent basis with set pricing. As a result, the Irgovel plant operations began to improve in November 2016 allowing Irgovel to begin repairing vendor relationships overall. First quarter Brazil segment revenues for 2017 increased 48% versus prior year and the plant operated at 58% of targeted capacity. While this represents a significant improvement, achieving positive cash flows remains a challenge. We continue to closely monitor Irgovel’s operations and related funding requirements.

BUSINESS

BUSINESS	3 Months Ended
	Mar. 31, 2017
BUSINESS [Abstract]
BUSINESS	NOTE 3. BUSINESS We are an ingredient company serving food, animal nutrition and specialty markets focused on value-added processing and marketing of healthy, natural and nutrient dense products derived from raw rice bran, an underutilized by-product of the rice milling industry. We apply our proprietary and patented technologies and intellectual properties to convert raw rice bran into numerous high value products including stabilized rice bran (SRB), rice bran oil (RBO), defatted rice bran (DRB), RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a highly nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance, and ProRyza, rice bran protein-based products, and a variety of other valuable derivatives extracted from these core products. Our target markets are natural food, functional food, nutraceutical supplement and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally. We have two reportable operating segments: (i) USA segment, which manufactures and distributes SRB (for food and animal nutrition customers) in various granulations along with Stage II products and derivatives and (ii) Brazil segment, which extracts crude RBO and DRB from rice bran, which are then further processed into fully refined rice bran oil for sale internationally and in Brazil, compounded animal nutrition products for horses, cows, swine, sheep and poultry and a number of valuable food and animal nutrition products derivatives and co-products. Stage II refers to the proprietary, patented processes run at our Dillon, Montana facility and includes products produced at that facility. In addition, we incur corporate and other expenses not directly attributable to reportable operating segments, which include costs related to our corporate staff, general and administrative expenses including public company expenses, intellectual property, professional fees, and other expenses. No corporate allocations, including interest, are made to the reportable operating segments. The combined operations of our USA and Brazil segments encompass our approach to processing raw rice bran into various high quality, value-added constituents and finished products. Over the past decade, we have developed and optimized our proprietary processes to support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods, nutritional supplements, nutraceuticals and high-end animal nutrition and health products. The USA segment produces SRB inside two supplier rice mills in California and our facility in Mermentau, Louisiana. Our facility located in Lake Charles, Louisiana has been idle since May 2009 but has recently been utilized as a warehouse. The USA segment also includes our Dillon, Montana Stage II facility which produces our Stage II products: RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a highly nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance, and ProRyza, rice bran protein-based products, and a variety of other valuable derivatives extracted from these core products. The manufacturing facilities included in our USA segment have proprietary processing equipment and process patented technology for the stabilization and further processing of rice bran into finished products. The Brazil segment consists of the consolidated operations of Nutra SA, whose only operating subsidiary is Irgovel, located in Pelotas, Brazil. Irgovel manufactures RBO and DRB products for both the food ingredient and animal nutrition markets in Brazil and internationally. In refining RBO to an edible grade, several co-products are obtained. One such product is distilled fatty acids, a valuable raw material for the detergent industry. Irgovel also produces rice lecithin, which has application in food ingredient products, animal nutrition and industrial applications. DRB is compounded with a number of other ingredients to produce complex animal nutrition products which are packaged and sold under Irgovel brands in the Brazilian market, sold as a raw material for further processing into food ingredient products or sold in bulk into the animal nutrition markets in Brazil and neighboring countries.

LOSS PER SHARE (EPS)

LOSS PER SHARE (EPS)	3 Months Ended
	Mar. 31, 2017
LOSS PER SHARE (EPS) [Abstract]
LOSS PER SHARE (EPS)	NOTE 4. LOSS PER SHARE (EPS) Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our Series F Convertible Preferred Stock (the “Series F Preferred Stock”) and Series G Convertible Preferred Stock (the “Series G Preferred Stock”) are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses . Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies shareholders by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effect of outstanding options, warrants and nonvested shares that vest solely on the basis of a service condition is calculated using the treasury stock method. The dilutive effects of the Preferred Stocks are calculated using the if-converted method. Below are reconciliations of the numerators and denominators in the EPS computations for the three months ended March 31, 2017 and 2016. Three Months Ended 2017 2016 NUMERATOR (in thousands): Basic and diluted - net loss attributable to RiceBran Technologies shareholders $ (2,282 ) $ 300 Dividend on preferred stock--beneficial conversion feature (778 ) (551 ) Basic and diluted - net loss attributable to RiceBran Technologies common shareholders $ (3,060 ) $ (251 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 9,657,543 9,215,684 Effect of dilutive securities outstanding - - Diluted EPS - weighted average number of shares outstanding 9,657,543 9,215,684 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 195,273 357,386 Warrants 17,635,102 8,712,124 Nonvested stock 256,840 867,086 Convertible preferred stock 3,054,435 835,165 The impact of potentially dilutive securities outstanding at March 31, 2017 and 2016, was not included in the calculation of diluted EPS for the three months ended March 31, 2017 for the periods presented

REDEEMABLE NONCONTROLLING INTER

REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA	3 Months Ended
	Mar. 31, 2017
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA [Abstract]
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA	NOTE 5. REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA We hold a variable interest which relates to our equity interest in Nutra SA (see Note 3). Our variable interest in Nutra SA is our Brazil segment. We are the primary beneficiary of Nutra SA, and as such, Nutra SA’s assets, liabilities and results of operations are included in our condensed consolidated financial statements. The other equity holders’ (Investors) interests are reflected in net loss attributable to noncontrolling interest in Nutra SA in the condensed consolidated statements of operations and accumulated deficit attributable to noncontrolling interest in Nutra SA in the condensed consolidated balance sheets. A summary of the carrying amounts of Nutra SA balances included in our condensed consolidated balance sheets follows (in thousands). March 31, 2017 December 31, 2016 Cash and cash equivalents $ 85 $ 109 Other current assets (restricted $618 and $398) 2,174 1,696 Property and equipment, net (restricted $2,599 and $2,481) 11,052 10,889 Other noncurrent assets 1,319 1,326 Total assets $ 14,630 $ 14,020 Current liabilities $ 8,320 $ 8,031 Current portion of long-term debt (nonrecourse) 7,399 6,816 Total liabilities $ 15,719 $ 14,847 Nutra SA’s debt is secured by its accounts receivable and property. The non-Brazilian entities within the consolidated ownership group do not guarantee any of Nutra SA’s debt. Cash provided by operations in our Brazil segment is generally unavailable for distribution to our Corporate and USA segments pursuant to the terms of the limited liability company agreement of Nutra SA (LLC Agreement). A summary of changes in redeemable noncontrolling interest in Nutra SA for the three months ended March 31, 2017 and 2016 (in thousands) follows. Three Months Ended 2017 2016 Redeemable noncontrolling interest in Nutra SA, beginning of period $ (699 ) $ 69 Investors' interest in net loss of Nutra SA (318 ) (438 ) Investors' interest in accumulated other comprehensive loss of Nutra SA 51 145 Investors' purchase of additional units 550 - Redeemable noncontrolling interest in Nutra SA, end of period $ (416 ) $ (224 ) Investors' average interest in Nutra SA during the period 35.0 % 31.7 % Investors' interest in Nutra SA at the end of the period 35.7 % 32.5 % The Investors have drag along rights which provide the Investors the ability to force a sale of Nutra SA assets after January 1, 2018. The right terminates upon the occurrence of certain events (a $50 million Nutra SA initial public offering or a change of control, as defined in the LLC Agreement). We may elect to exercise a right of first refusal to purchase the Investors’ interest instead of proceeding to a sale. We have assessed the likelihood of the Investors exercising these rights as less than probable at March 31, 2017. We will continue to evaluate the probability of the Investors exercising their drag along rights each reporting period. We will begin to accrete the redeemable noncontrolling interest up to fair value if and when it is probable the Investors will exercise these rights. As the result of an amendment effective March 31,2017, the Investors right to elect to exchange units in Nutra SA for our common stock terminated. In exchange for the termination of this right, we paid the Investors $0.1 million. Under the LLC Agreement, the business of Nutra SA is to be conducted by the manager, currently our CEO, subject to the oversight of the management committee. The management committee is comprised of three of our representatives and two Investor representatives. Upon an event of default or a qualifying event, we will no longer control the management committee and the management committee will include three Investor representatives and two of our representatives. In addition, following an event of default or a qualifying event, a majority of the members of the management committee may replace the manager of Nutra SA. As of March 31, 2017, there have been no unwaived events of default. Events of default, as defined in the Membership Interest Purchase Agreement (MIPA) and the October 2013 amendment of investment agreements, are failure of Irgovel to meet minimum annual processing targets or failure to achieve EBITDA on a local currency basis of at least R$4.0 million annually. As of March 31, 2017, there have been no qualifying events. The LLC Agreement defines a qualifying event as the bankruptcy of RiceBran Technologies or Nutra SA. In evaluating whether we are the primary beneficiary of Nutra SA, we considered the matters which could be put to a vote of the members. Until there is an event of default or a qualifying event, the Investors’ rights and abilities, individually or in the aggregate, do not allow them to substantively participate in the operations of Nutra SA. The Investors do not currently have the ability to dissolve Nutra SA or otherwise force the sale of all its assets. However, the Investors do have drag along rights in the future. We will continue to evaluate whether we are the primary beneficiary of Nutra SA each reporting period.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2017
DEBT [Abstract]
DEBT	NOTE 6. DEBT The following table summarizes current and long-term portions of debt (in thousands): March 31, 2017 December 31, 2016 Corporate segment: Senior debentures, net, maturing in February 2019, principal $6.6 million $ 415 $ - Subordinated notes, net, maturing in May 2019, principal $5.9 million 5,094 6,310 Other 94 119 Senior revolving loan - 1,725 Senior term loan, net - 917 5,603 9,071 Brazil segment: Capital expansion loans 2,571 2,454 Working capital lines of credit 702 401 Advances on customer export orders 1,117 1,113 Special tax programs 2,927 2,767 Other 83 81 7,400 6,816 Total debt 13,003 15,887 Current portion 7,435 9,878 Long-term portion $ 5,568 $ 6,009 Corporate Segments We issued senior debentures in the principal amount of $6.6 million and related warrants in a private placement,in February 2017 . The transaction, and the accounting therefore, is Under the debenture agreements, the USA segment is required to have adjusted EBITDA, as defined in the agreement of not less than $325 thousand, $756 thousand, $483 thousand and $461 thousand in the quarters ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017. In connection with the senior debenture private placement, in February 2017, we entered into agreements that resulted in (i) a reduction in the annual interest rate on the subordinated notes from 11.75% to 7%, (ii) an extension of the maturity date of the subordinated notes to May 2019 from May 2018 and (iii) our first quarter 2017 payment of $0.2 million of note principal and $0.3 million of accrued note interest. The entire transaction, and its accounting consequences, are Brazil Segment As of March 31, 2017, Brazil had approximately $0.7 million (USD) of installment payments in arrears. The banks have not called these loans in default, and management continues to work with the lenders to renegotiate payment terms, however, all Brazil segment debt has been classified as current in the accompanying consolidated balance sheet as of March 31, 2017. All Brazil segment debt is denominated in the Brazilian Real (R$), except advances on customer export orders which are denominated in U.S. Dollars.

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	3 Months Ended
	Mar. 31, 2017
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	NOTE 7. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS Preferred Common Shares Common Accumulated Accumulated Deficit Attributable to Noncontrolling Interest in Accumulated Other Comprehensive Equity Balance, December 31, 2016 $ - $ 10,790,351 $ 264,232 $ (259,819 ) $ (699 ) $ (4,346 ) (632 ) Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes - 108,696 269 - - - 269 Dividend on preferred stock - beneficial conversion feature - - 778 (778 ) - - - Modification of senior debenture holder warrants - - 582 - - - 582 Modification of subodinated note holder warrants - - 117 - - - 117 Change in classification of preferred stock to equity from liability 1,545 * - - - - - 1,545 Change in classification of warrants to equity from from liability - - 7,851 - - - 7,851 Other - 28,157 24 - - - 24 Accumulated deficit attributable to noncontrolling interest in Nutra SA - - - - 283 - 283 Foreign currency translation - - - - - 94 94 Net loss - - - (2,282 ) - - (2,282 ) Balance, March 31, 2017 $ 1,545 $ 10,927,204 $ 273,853 $ (262,879 ) $ (416 ) $ (4,252 ) $ 7,851 * Series F preferred stock, 3,000 shares outstanding; Series G pereferred stock, 2,000 shares outstanding A summary of warrant activity for the three months ended March 31, 2017, follows. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2016 6,364,110 5.77 2.4 4,474,868 $ 1.82 3.3 Issued - NA NA 11,783,163 0.96 5.0 Impact of repricing debenture purchaser warrants: Prior to repricing (875,000 ) 5.49 2.1 - NA NA After repricing 875,000 0.96 5.5 - NA NA Impact of repricing subordinated note holder warants: Prior to repricing (289,669 ) 5.25 3.3 - NA NA After repricing 289,669 0.96 3.3 - NA NA Impact of anti-dilution clauses: Prior to impact - NA NA (1,489,868 ) 1.50 0.8 After impact - NA NA 2,327,919 0.96 0.8 Transfer from liability to equity 14,468,163 1.16 4.79 (14,468,163 ) 1.16 4.79 Exercised - NA NA - NA NA Forfeited, expired or cancelled - NA NA - NA NA Outstanding, March 31, 2017 20,832,273 $ 2.32 4.2 2,627,919 $ 1.03 0.9 Exercisable, March 31, 2017 19,527,273 $ 2.38 4.1 2,627,919 $ 1.03 0.9 Common Stock In February 2017, shareholders approved and we filed an amendment to our articles of incorporation increasing our authorized shares of common stock from 25,000,000 to 50,000,000. On February 14, 2017, we issued a former employee 108,696 shares of our common stock, in lieu of paying $100,000 cash for a 2016 bonus. The chairman of our board was awarded transitional director compensation in the amount of (i) $10,000 or 7,035 shares per month for July 2016 through December 2016 and (ii) $8,333 or 9,027 shares per month for January 2017 through March 2017. The amount is to be paid in either cash or stock at the chairman’s election. As of the date of this filing no election has been made. Share Sequencing From June 2015 until March 2017, the minority interest holders in Nutra SA could elect , the number of common shares and warrants issuable upon this election, was variable and indeterminate. For accounting purposes, we were not able to conclude that we had sufficient authorized and unissued shares to settle all contracts subject to the GAAP derivative guidance during the period the minority interest holders had this right, which terminated March 31, 2017. Our adopted sequencing approach (Share Sequencing) was based on earliest issuance date, therefore, we were required to carry warrants issued between June 2015 and March 2017, at fair value, as derivative warrant liabilities, and preferred stock issued between June 2015 and March 2017, Transactions with Preferred Stock Holders. In February 2017, we issued and sold 2,000 shares of Series G preferred stock. The Series G preferred stock is non-voting and may be converted into a total of 1,897,983 shares of our common stock at the holders’ election at any time, subject to certain beneficial ownership limitations, at a ratio of 1 preferred share for 948.9915 shares of common stock. The Series G preferred stock is entitled to receive dividends if we pay dividends on our common stock, in which case the holders of Series G preferred stock are entitled to receive the amount and form of dividends that they would have received if they held the common stock that is issuable upon conversion of the Series G preferred stock. If we are liquidated or dissolved, the holders of Series G preferred stock are entitled to receive, before any amounts are paid in respect of our common stock, an amount per share of Series G preferred stock equal to $1,000, plus any accrued but unpaid dividends thereon. In February 2017, in conjunction with the sale of the Series G preferred stock, we also sold warrants to purchase 1,423,488 shares of common stock (exercise price of $0.96 per share, exercisable beginning in February 2017 and expiring in February 2022). A subordinated note holder exchanged subordinated notes with a principal and carrying value of $0.1 million and cash for 180 shares of the Series G preferred stock and related warrants, which was treated as an extinguishment of debt. The net cash proceeds from the sale was $1.7 million, after deducting allocated cash offering expenses of $0.1 million. On the date of issuance, we allocated $1.0 million of the proceeds to derivative warrant liability, to record the warrants at fair value, recorded a $0.1 million loss on extinguishment and reduced debt $0.1 million related to the subordinated noteholders exchange, and recorded $1.2 million as preferred stock. We recorded a $0.8 million dividend on preferred stock for the preferred stock beneficial conversion feature equal to the proceeds allocated to the preferred stock issued to purchases who did not exchange debt, as the fair value of the common stock underlying the convertible preferred stock at issuance exceeded the amount recorded in preferred stock. Transactions with Senior Debenture Holders On February 2017, we sold and issued in a private placement, for an aggregate subscription amount of $6.0 million: (i) senior debentures in the principal amount of $6.6 million and (ii) warrants to purchase an aggregate of 6,875,000 shares of common stock (exercise price of $0.96 per share, exercisable beginning February 2017 and expiration February 2022). We received aggregate net proceeds of $5.5 million, after deducting placement agent fees and allocated expenses of $0.5 million. Concurrently, we amended existing warrants, held by the debenture purchasers, for the purchase of up to 875,000 shares to (i) reduce the exercise prices from an average $5.49 per share to $0.96 per share, providing the warrants are not exercisable until August 2017, and (ii) change the expiration dates to August 2022, which increased the average remaining term of the warrants from 2.1 years to 5.5 years. We recorded $4.6 million as an increase to derivative warrant liabilities, to record the warrants at their fair value on the date of issuance, the $0.5 million as an increase in common stock to record the change in fair value of existing warrants and the remaining $0.4 million to debt, debt issuance costs and debt discount. We used the net proceeds from the offering to (i) pay off the senior revolving loan and term loan debt totaling $3.8 million and (ii) pay $0.2 million of principal and $0.3 million of interest due on subordinated notes and (iii) for working capital and general corporate purposes. We filed a registration statement on Form S-3, which became effective in May 2017, to register the shares under the warrants issued to the senior debenture purchasers Transaction with Subordinated Note Holders In connection with the February 2017 senior debenture private placement, we entered into agreements which resulted in (i) a reduction in the annual interest rate on the subordinated notes from 11.75% to 7% (ii) an extension of the maturity date of the subordinated notes to May 2019 from May 2018 (iii) the payment of an aggregate amount equal to $0.5 million on the subordinated notes; (iv) the issuance of warrants to purchase up to 3,484,675 shares of our common stock (exercise price of $0.96 per share, expiration February 2022); and (v) the amendment of existing warrants held by the subordinated note holders for the purchase 289,669 shares of common stock to reduce the exercise price from $5.25 per share to $0.96 per share. We accounted for the transaction as an extinguishment of debt and issuance of new debt. On the transaction date we (i) recorded a loss on extinguishment of debt of $1.5 million, (ii) adjusted subordinated notes payable debt down by $0.9 million, to its fair value as of the transaction date, (iii) increased derivative liability $2.3 million, representing the fair value of the newly issued warrants, and (iv) increased common stock $0.1 million for the change in the fair value of the existing warrants Full Ratchet Anti-Dilution As a result of the February 2017 transactions described above, the exercise price of certain warrants that contain full ratchet anti-dilution provisions was reduced from $1.50 per share to $0.96 per share and the number of shares of common stock underlying these warrants increased from 1,489,868 shares to 2,327,919 shares. Option Issuances In March 2017, we granted our chief executive officer an option to purchase 100,000 shares of our common stock at an exercise price of $0.76 per share. The option vests as to 25,000 shares in August 2017 and the remaining shares vest in monthly instalments through August 2020. In April 2017, we granted options to purchase an aggregate 345,500 shares of our common stock to executive officers and employees. The options vest in four equal annual instalments beginning in April 2018 at an exercise price of $0.85 per share. Contingent Restricted Stock Unit Awards In March 2017, our compensation committee approved a resolution proposing the award of restricted stock units (RSUs) under the 2014 Equity Incentive Plan to our executive officers covering a total of 1,175,000 shares of our common stock subject to and effective upon shareholder approval of a 1,700,000 increase in the authorized shares issuable under the 2014 Equity Incentive Plan. The committee believes the RSUs are an incentive designed to align the interests of executive management with shareholder value. If the increase in authorized shares is approved, the RSUs would be granted and would be effective on the fifth business day after the date of our annual shareholders meeting. The annual shareholders meeting is currently scheduled to occur on June 21, 2017. The shares subject to RSU would vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Each RSU’s shares would vest (i) 10% if the vesting price equals or exceeds $5.00 per share, (ii) 30% if the vesting price equals or exceeds $10.00 per share and (iv) 60% if the vesting price equals or exceeds $15.00 per share. The following table summarizes information related to outstanding warrants as March 31, 2017 and December 31, 2016: March 31, 2017 December 31, 2016 Range of Exercise Prices Type of Warrant Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) $ 0.96 Liability (1) 2,327,919 $ 0.96 0.7 - $ - - $ 0.96 Equity 12,947,832 0.96 3.1 - - - $ 1.50 Liability (2) 300,000 1.60 3.1 - - - $ 1.50 to $1.60 Liability (1)(2) - - - 1,789,868 1.52 1.3 $ 2.00 Liability (3) - - - 2,660,000 2.00 4.6 $ 2.00 Equity 2,660,000 2.00 4.2 - - - $ 5.25 Liability (3) - - - 25,000 5.25 3.6 $ 5.25 to $5.87 Equity 3,156,670 5.33 2.5 4,296,339 5.36 2.7 $ 6.55 to $16.80 Equity 2,067,771 6.61 1.7 2,067,771 6.61 2.0 23,460,192 $ 2.17 3.8 10,838,978 $ 1.30 0.5 (1) Includes two warrants which contain full ratchet anti-dilution provisions and are classified as derivative warrant liabilities in our balance sheets. Under the anti-dilution clauses contained in these warrants, in the event of equity issuances (i.e. issuances of our common stock, certain awards of stock options to employees, and issuances of warrants and/or other convertible instruments) at prices below the exercise prices of these warrants, we are required to lower the exercise price on these warrants and increase the number of shares underlying these warrants. (2) Includes a warrant for the purchase of 300,000 shares of our common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event of issuances of stock options and/or convertible instruments with anti-dilution provisions (providing for the adjustment of the exercise price, conversion price or other price or rate at which shares of common stock thereunder may be purchased, acquired or converted, and/or any upward adjustment in the number of shares of common stock issuable) we may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant. (3) The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2017
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 8. FAIR VALUE MEASUREMENTS The fair value of cash and cash equivalents, accounts and other receivables and accounts payable approximates their carrying value due to their shorter maturities. As of March 31, 2017, the fair value of our Corporate segment debt (Level 3 measurement) is approximately $4.5 million higher than the $5.6 million carrying value of that debt, based on current market rates for similar debt with similar maturities. The fair value of our Brazil segment debt (Level 3 measurement) approximates the $7.3 million carrying value of that debt based on the current market rates for similar debt with similar maturities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Certain assets and liabilities are presented in the financial statements at fair value. Assets and liabilities measured at fair value on a recurring basis include derivative warrant and conversion liabilities. Assets and liabilities measured at fair value on a non-recurring basis may include property. We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market: ● Level 1 – inputs include quoted prices for identical instruments and are the most observable. ● Level 2 – inputs include quoted prices for similar assets and observable inputs such as interest rates, currency exchange rates and yield curves. ● Level 3 – inputs are not observable in the market and include management’s judgments about the assumptions market participants would use in pricing the asset or liability. For instruments measured using Level 3 inputs, a reconciliation of the beginning and ending balances is disclosed. The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our condensed consolidated balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of March 31, 2017 - derivative warrant liabilities $ - $ - $ (494 ) $ (494 ) Total liabilities at fair value, as of December 31, 2016 - derivative warrant liabilities $ - $ - $ (1,527 ) $ (1,527 ) Warrants accounted for as derivative liabilities are valued using the lattice model each reporting period and the resultant change in fair value is recorded in the condensed consolidated statements of operations. The lattice model requires us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants. The risk-free interest rate is determined by reference to the treasury yield curve rate of instruments with the same term as the warrant. Additional assumptions that were used to calculate fair value follow. March 31, 2017 December 31, 2016 Risk-free interest rate 0.8% 0.6% -1.9% (0.8% weighted average) (1.6% weighted average) Expected volatility 80% 64% (80% weighted average) (64% weighted average) The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands). Total Level 3 Fair Value Fair Value as of Beginning of Period Total Unrealized Gains (Losses) Issuance of New Instruments Reclassify to (Deficit) Equity Fair Value, at End of Period (1) Three Months Ended March 31, 2017, derivative warrant liabilities $ (1,527 ) $ 1,099 $ (7,917 ) $ 7,851 $ (494 ) Three Months Ended March 31, 2016, derivative warrant liabilities $ (678 ) $ 811 $ (2,473 ) $ - $ (2,340 ) (1) Included in change in fair value of derivative warrant liabilities in our unaudited condensed consolidated statements of operations.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2017
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9. COMMITMENTS AND CONTINGENCIES In addition to the matters discussed below, from time to time we are involved in litigation incidental to the conduct of our business in the USA and Brazil. These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. Defense costs are expensed as incurred and are included in professional fees. Irgovel Litigation Irgovel is a defendant in several labor claims, mainly related to overtime, illnesses allegedly contracted at work and work-related injuries and salary related matters for periods prior to the acquisition of Irgovel by RiceBran. The labor suits are mainly in the lower courts, and for the majority of the cases a decision for the dismissal of the claims has been granted. None of these labor claims is individually significant. Management believes it’s unlikely there will be a judgment against Irgovel, however, in the event the court does issue a judgment against Irgovel, it could be approximately $0.9 million. Irgovel accrues for losses on tax and other legal contingencies when it has a present obligation, formalized or not, as a result of a past event, it is probable that an outflow of resources will be required to settle the obligation and the amount of the obligation can be reliably estimated. Irgovel is a party to several other pending litigations and administrative proceedings at the Federal, State and Municipal level. The assessment of the likelihood of an unfavorable outcome in these litigations and proceedings includes the analysis of the evidence available, the hierarchy of the applicable laws, available former court decisions, as well as the most recent court decisions and their importance to the Brazilian legal system, as well as the opinions of our external and in-house legal counsels. We record amounts considered sufficient by our management to cover probable losses based on these elements. Irgovel - Events of Default As further described in Note 5, Irgovel is required to meet minimum annual processing targets or to achieve EBITDA on a local currency basis of at least R$4.0 million annually. If not achieved, this would result in an event of default under our existing agreements with the Investors. It is possible that an event of default may be triggered as of December 31, 2017 and a waiver of non-compliance may not be obtained from the Investors. Employment Contracts and Severance Payments We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control. In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2017
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10. RELATED PARTY TRANSACTIONS Transactions with Baruch Halpern Prior to 2017, entities beneficially owned by Baruch Halpern, a director, invested in our subordinated notes and related warrants prior to 2014. As of March 31, 2017, and throughout the first quarter of 2017, Mr. Halpern beneficially held approximately 43% of our outstanding subordinated notes and related warrants. See Note 7 for information related to the modification of the subordinated notes, repricing of related warrants and the issuance of warrants to subordinated note holders in February 2017. In the three months ended March 31, 2017 and 2016, we expensed $0.1 million and paid $0.2 million, of interest on the subordinated notes beneficially owned by Mr. Halpern.

FAILURE TO COMPLY WITH NASDAQ L

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	3 Months Ended
	Mar. 31, 2017
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	NOTE 11. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS On August 18, 2016, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we have failed to comply with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires that companies listed on the Nasdaq Capital Market maintain a minimum of $2.5 million in stockholders’ equity for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1) We submitted our plan to regain compliance in October 2016. On November 15, 2016, based on information we submitted to Nasdaq, the Staff granted us the maximum allowable 180-day extension to February 14, 2017 to evidence compliance with the minimum stockholders’ equity requirement. On February 16, 2017, we received a determination letter from the Nasdaq Listing Qualifications Staff stating that we had not regained compliance with the minimum stockholders’ equity requirement. The letter also stated our common stock would be delisted from The Nasdaq Capital Market at the opening of business on February 27, 2017 unless we request a hearing before the Nasdaq Hearing Panel. We requested and were granted a hearing before the panel to appeal the Letter on March 30, 2017. After that hearing, o n April 24, 2017, we received a decision letter from Nasdaq stating that the panel granted the request we made at the hearing for continued listing provided that, on or before May 15, 2017, we have announced that our equity is over $2.5 million. We must also at that time provide the panel with updated projections showing stockholders’ equity through May 2018. As reported herein our equity is $7.9 million and exceeds the minimum as of March 31, 2017. On March 10, 2017, we received a notification letter from Nasdaq indicating that we have failed to comply with the minimum bid price requirement of Nasdaq List Rule 5550(a)(2). If this appears unlikely as September 6, 2017, approaches, we are committed to taking actions that would enable us to regain compliance, including, if necessary, completing a reverse split of our common stock to increase its share price above the $1 minimum bid price. There can be no assurance that we will meet the minimum stockholders’ equity requirement or the minimum bid price requirement during any compliance period or in the future, or otherwise meet Nasdaq compliance standards, or that Nasdaq will grant us any relief from delisting as necessary, or that we will be able to ultimately meet applicable Nasdaq requirements for any such relief.

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2017
SEGMENT INFORMATION [Abstract]
SEGMENT INFORMATION	NOTE 12. SEGMENT INFORMATION The tables below Three Months Ended March 31, 2017 Corporate USA Brazil Consolidated Revenues $ - $ 8,032 $ 3,403 $ 11,435 Cost of goods sold - 5,449 3,475 8,924 Gross profit - 2,583 (72 ) 2,511 Depreciation and amortization (in selling, general and administrative) (16 ) (82 ) (16 ) (114 ) Other operating expense (1,375 ) (1,020 ) (518 ) (2,913 ) Income (loss) from operations $ (1,391 ) $ 1,481 $ (606 ) $ (516 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (3,124 ) $ 1,481 $ (639 ) $ (2,282 ) Interest expense 1,057 - 349 1,406 Depreciation (in cost of goods sold) - 204 265 469 Purchases of property - 53 79 132 Three Months Ended March 31, 2016 Corporate USA Brazil Consolidated Revenues $ - $ 7,754 $ 2,297 $ 10,051 Cost of goods sold - 5,294 2,520 7,814 Gross profit - 2,460 (223 ) 2,237 Depreciation and amortization (in selling, general and administrative) (23 ) (314 ) (11 ) (348 ) Other operating expense (1,274 ) (1,375 ) (730 ) (3,379 ) Loss from operations $ (1,297 ) $ 771 $ (964 ) $ (1,490 ) Net income (loss) attributable to RiceBran Technologies shareholders $ 433 $ 771 $ (904 ) $ 300 Interest expense 679 - 412 1,091 Depreciation (in cost of goods sold) - 179 194 373 Purchases of property - 65 143 208 The tables below Corporate USA Brazil Consolidated As of March 31, 2017 Inventories $ - $ 2,850 $ 1,178 $ 4,028 Property and equipment, net 378 7,451 11,052 18,881 Goodwill - 790 - 790 Intangible assets, net - 206 - 206 Total assets 3,873 13,960 14,630 32,463 As of December 31, 2016 Inventories - 2,848 925 3,773 Property and equipment, net 392 7,652 10,889 18,933 Goodwill - 790 - 790 Intangible assets, net - 242 - 242 Total assets 1,339 13,486 14,020 28,845 The following table presents revenue by geographic area for the three months ended March 31, 2017 and 2016 (in thousands). Three Months Ended 2017 2016 United States $ 6,927 $ 7,029 Brazil 2,918 2,087 Other international 1,590 935 Total revenues $ 11,435 $ 10,051

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2017
BASIS OF PRESENTATION [Abstract]
Recent Accounting Standards	Recent Accounting Standards Recent accounting standards not yet adopted In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and International Financial Reporting Standards. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. An entity may choose to adopt the new standard either retrospectively or through a cumulative effect adjustment as of the start of the first period for which it applies the new standard. The guidance is effective for our annual and interim periods beginning in 2018, however, early adoption is permitted. We have begun to evaluate the impact that adoption of this guidance will have on our consolidated financial statements but have not completed the evaluation and implementation process. We have not yet selected a transition method but have determined that we will utilize the deferred effective date of January 1, 2018, to adopt the standard. In February 2016, the FASB issued guidance which changes the accounting for leases. Under prior GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on the lease’s classification as a finance or operating lease. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest expense on the lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard. In June 2016, the FASB issued a new credit loss standard that replaces the incurred loss impairment methodology in current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It is effective for annual reporting periods beginning after December 15, 2019 and interim periods within those annual periods. Early adoption for fiscal years beginning after December 15, 2018 is permitted. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first effective reporting period. We have not yet determined the impact that the new guidance will have on our results of operations, financial position and cash flows and have not yet determined if we will early adopt the standard Recently adopted accounting standards In January 2017, the FASB issued a new goodwill impairment standard that simplifies the goodwill impairment testing methodology. The new standard eliminates Step 2 of the goodwill impairment test, in which an entity determines the fair value at the test date of its assets and liabilities using the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. It is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We adopted the standard as of January 1, 2017, with no effect on our financial position or results of operations. In March 2016, the FASB issued new guidance that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The guidance also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. The guidance is effective for our annual and interim periods beginning in 2017 with early adoption permitted. We adopted the standard in the first quarter of 2017 and changed our accounting policy to recognize forfeitures as they occur. This change did not have a material effect on our results of operations as we previously did not apply an estimated forfeiture rate to restricted stock awards to our officers and directors. Additionally, most of our outstanding stock option awards vest on a monthly basis over the vesting period (generally three or four years). As these awards do not have performance conditions, the expense is recognized each month on a straight-line basis and excludes the effect of the estimated forfeiture rate as there was no risk of expensing awards that would be subsequently forfeited prior to vesting.

LOSS PER SHARE (EPS) (Tables)

LOSS PER SHARE (EPS) (Tables)	3 Months Ended
	Mar. 31, 2017
LOSS PER SHARE (EPS) [Abstract]
Reconciliations of numerators and denominators in EPS computations	Below are reconciliations of the numerators and denominators in the EPS computations for the three months ended March 31, 2017 and 2016. Three Months Ended 2017 2016 NUMERATOR (in thousands): Basic and diluted - net loss attributable to RiceBran Technologies shareholders $ (2,282 ) $ 300 Dividend on preferred stock--beneficial conversion feature (778 ) (551 ) Basic and diluted - net loss attributable to RiceBran Technologies common shareholders $ (3,060 ) $ (251 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 9,657,543 9,215,684 Effect of dilutive securities outstanding - - Diluted EPS - weighted average number of shares outstanding 9,657,543 9,215,684 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 195,273 357,386 Warrants 17,635,102 8,712,124 Nonvested stock 256,840 867,086 Convertible preferred stock 3,054,435 835,165

REDEEMABLE NONCONTROLLING INT21

REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA (Tables)	3 Months Ended
	Mar. 31, 2017
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA [Abstract]
Summary of the carrying amounts included in consolidated balance sheets	A summary of the carrying amounts of Nutra SA balances included in our condensed consolidated balance sheets follows (in thousands). March 31, 2017 December 31, 2016 Cash and cash equivalents $ 85 $ 109 Other current assets (restricted $618 and $398) 2,174 1,696 Property and equipment, net (restricted $2,599 and $2,481) 11,052 10,889 Other noncurrent assets 1,319 1,326 Total assets $ 14,630 $ 14,020 Current liabilities $ 8,320 $ 8,031 Current portion of long-term debt (nonrecourse) 7,399 6,816 Total liabilities $ 15,719 $ 14,847
Summary of changes in redeemable noncontrolling interest	A summary of changes in redeemable noncontrolling interest in Nutra SA for the three months ended March 31, 2017 and 2016 (in thousands) follows. Three Months Ended 2017 2016 Redeemable noncontrolling interest in Nutra SA, beginning of period $ (699 ) $ 69 Investors' interest in net loss of Nutra SA (318 ) (438 ) Investors' interest in accumulated other comprehensive loss of Nutra SA 51 145 Investors' purchase of additional units 550 - Redeemable noncontrolling interest in Nutra SA, end of period $ (416 ) $ (224 ) Investors' average interest in Nutra SA during the period 35.0 % 31.7 % Investors' interest in Nutra SA at the end of the period 35.7 % 32.5 %

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2017
DEBT [Abstract]
Current and long-term debt	The following table summarizes current and long-term portions of debt (in thousands): March 31, 2017 December 31, 2016 Corporate segment: Senior debentures, net, maturing in February 2019, principal $6.6 million $ 415 $ - Subordinated notes, net, maturing in May 2019, principal $5.9 million 5,094 6,310 Other 94 119 Senior revolving loan - 1,725 Senior term loan, net - 917 5,603 9,071 Brazil segment: Capital expansion loans 2,571 2,454 Working capital lines of credit 702 401 Advances on customer export orders 1,117 1,113 Special tax programs 2,927 2,767 Other 83 81 7,400 6,816 Total debt 13,003 15,887 Current portion 7,435 9,878 Long-term portion $ 5,568 $ 6,009

EQUITY, SHARE-BASED COMPENSAT23

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2017
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
Summary of equity activity	Preferred Common Shares Common Accumulated Accumulated Deficit Attributable to Noncontrolling Interest in Accumulated Other Comprehensive Equity Balance, December 31, 2016 $ - $ 10,790,351 $ 264,232 $ (259,819 ) $ (699 ) $ (4,346 ) (632 ) Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes - 108,696 269 - - - 269 Dividend on preferred stock - beneficial conversion feature - - 778 (778 ) - - - Modification of senior debenture holder warrants - - 582 - - - 582 Modification of subodinated note holder warrants - - 117 - - - 117 Change in classification of preferred stock to equity from liability 1,545 * - - - - - 1,545 Change in classification of warrants to equity from from liability - - 7,851 - - - 7,851 Other - 28,157 24 - - - 24 Accumulated deficit attributable to noncontrolling interest in Nutra SA - - - - 283 - 283 Foreign currency translation - - - - - 94 94 Net loss - - - (2,282 ) - - (2,282 ) Balance, March 31, 2017 $ 1,545 $ 10,927,204 $ 273,853 $ (262,879 ) $ (416 ) $ (4,252 ) $ 7,851 * Series F preferred stock, 3,000 shares outstanding; Series G pereferred stock, 2,000 shares outstanding
Summary of warrant activity	A summary of warrant activity for the three months ended March 31, 2017, follows. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2016 6,364,110 5.77 2.4 4,474,868 $ 1.82 3.3 Issued - NA NA 11,783,163 0.96 5.0 Impact of repricing debenture purchaser warrants: Prior to repricing (875,000 ) 5.49 2.1 - NA NA After repricing 875,000 0.96 5.5 - NA NA Impact of repricing subordinated note holder warants: Prior to repricing (289,669 ) 5.25 3.3 - NA NA After repricing 289,669 0.96 3.3 - NA NA Impact of anti-dilution clauses: Prior to impact - NA NA (1,489,868 ) 1.50 0.8 After impact - NA NA 2,327,919 0.96 0.8 Transfer from liability to equity 14,468,163 1.16 4.79 (14,468,163 ) 1.16 4.79 Exercised - NA NA - NA NA Forfeited, expired or cancelled - NA NA - NA NA Outstanding, March 31, 2017 20,832,273 $ 2.32 4.2 2,627,919 $ 1.03 0.9 Exercisable, March 31, 2017 19,527,273 $ 2.38 4.1 2,627,919 $ 1.03 0.9
Summary of outstanding warrants	The following table summarizes information related to outstanding warrants as March 31, 2017 and December 31, 2016: March 31, 2017 December 31, 2016 Range of Exercise Prices Type of Warrant Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) $ 0.96 Liability (1) 2,327,919 $ 0.96 0.7 - $ - - $ 0.96 Equity 12,947,832 0.96 3.1 - - - $ 1.50 Liability (2) 300,000 1.60 3.1 - - - $ 1.50 to $1.60 Liability (1)(2) - - - 1,789,868 1.52 1.3 $ 2.00 Liability (3) - - - 2,660,000 2.00 4.6 $ 2.00 Equity 2,660,000 2.00 4.2 - - - $ 5.25 Liability (3) - - - 25,000 5.25 3.6 $ 5.25 to $5.87 Equity 3,156,670 5.33 2.5 4,296,339 5.36 2.7 $ 6.55 to $16.80 Equity 2,067,771 6.61 1.7 2,067,771 6.61 2.0 23,460,192 $ 2.17 3.8 10,838,978 $ 1.30 0.5 (1) Includes two warrants which contain full ratchet anti-dilution provisions and are classified as derivative warrant liabilities in our balance sheets. Under the anti-dilution clauses contained in these warrants, in the event of equity issuances (i.e. issuances of our common stock, certain awards of stock options to employees, and issuances of warrants and/or other convertible instruments) at prices below the exercise prices of these warrants, we are required to lower the exercise price on these warrants and increase the number of shares underlying these warrants. (2) Includes a warrant for the purchase of 300,000 shares of our common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event of issuances of stock options and/or convertible instruments with anti-dilution provisions (providing for the adjustment of the exercise price, conversion price or other price or rate at which shares of common stock thereunder may be purchased, acquired or converted, and/or any upward adjustment in the number of shares of common stock issuable) we may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant. (3) The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2017
FAIR VALUE MEASUREMENTS [Abstract]
Fair values by input hierarchy of items measured at fair value on a recurring basis	The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our condensed consolidated balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of March 31, 2017 - derivative warrant liabilities $ - $ - $ (494 ) $ (494 ) Total liabilities at fair value, as of December 31, 2016 - derivative warrant liabilities $ - $ - $ (1,527 ) $ (1,527 )
Additional assumptions used to calculate fair value	Additional assumptions that were used to calculate fair value follow. March 31, 2017 December 31, 2016 Risk-free interest rate 0.8% 0.6% -1.9% (0.8% weighted average) (1.6% weighted average) Expected volatility 80% 64% (80% weighted average) (64% weighted average)
Changes in level 3 items measured at fair value	The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands). Total Level 3 Fair Value Fair Value as of Beginning of Period Total Unrealized Gains (Losses) Issuance of New Instruments Reclassify to (Deficit) Equity Fair Value, at End of Period (1) Three Months Ended March 31, 2017, derivative warrant liabilities $ (1,527 ) $ 1,099 $ (7,917 ) $ 7,851 $ (494 ) Three Months Ended March 31, 2016, derivative warrant liabilities $ (678 ) $ 811 $ (2,473 ) $ - $ (2,340 ) (1) Included in change in fair value of derivative warrant liabilities in our unaudited condensed consolidated statements of operations.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2017
SEGMENT INFORMATION [Abstract]
Segment information identified and reconciliations of segment information to total consolidated information	The tables below Three Months Ended March 31, 2017 Corporate USA Brazil Consolidated Revenues $ - $ 8,032 $ 3,403 $ 11,435 Cost of goods sold - 5,449 3,475 8,924 Gross profit - 2,583 (72 ) 2,511 Depreciation and amortization (in selling, general and administrative) (16 ) (82 ) (16 ) (114 ) Other operating expense (1,375 ) (1,020 ) (518 ) (2,913 ) Income (loss) from operations $ (1,391 ) $ 1,481 $ (606 ) $ (516 ) Net income (loss) attributable to RiceBran Technologies shareholders $ (3,124 ) $ 1,481 $ (639 ) $ (2,282 ) Interest expense 1,057 - 349 1,406 Depreciation (in cost of goods sold) - 204 265 469 Purchases of property - 53 79 132 Three Months Ended March 31, 2016 Corporate USA Brazil Consolidated Revenues $ - $ 7,754 $ 2,297 $ 10,051 Cost of goods sold - 5,294 2,520 7,814 Gross profit - 2,460 (223 ) 2,237 Depreciation and amortization (in selling, general and administrative) (23 ) (314 ) (11 ) (348 ) Other operating expense (1,274 ) (1,375 ) (730 ) (3,379 ) Loss from operations $ (1,297 ) $ 771 $ (964 ) $ (1,490 ) Net income (loss) attributable to RiceBran Technologies shareholders $ 433 $ 771 $ (904 ) $ 300 Interest expense 679 - 412 1,091 Depreciation (in cost of goods sold) - 179 194 373 Purchases of property - 65 143 208
Segment information for selected balance sheet accounts	The tables below Corporate USA Brazil Consolidated As of March 31, 2017 Inventories $ - $ 2,850 $ 1,178 $ 4,028 Property and equipment, net 378 7,451 11,052 18,881 Goodwill - 790 - 790 Intangible assets, net - 206 - 206 Total assets 3,873 13,960 14,630 32,463 As of December 31, 2016 Inventories - 2,848 925 3,773 Property and equipment, net 392 7,652 10,889 18,933 Goodwill - 790 - 790 Intangible assets, net - 242 - 242 Total assets 1,339 13,486 14,020 28,845
Revenue by geographic area	The following table presents revenue by geographic area for the three months ended March 31, 2017 and 2016 (in thousands). Three Months Ended 2017 2016 United States $ 6,927 $ 7,029 Brazil 2,918 2,087 Other international 1,590 935 Total revenues $ 11,435 $ 10,051

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2017
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years

LIQUIDITY, GOING CONCERN AND 27

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN (Details) - USD ($) $ in Thousands	Apr. 30, 2017	Feb. 28, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Line of Credit Facility [Abstract]
Proceeds from preference stock and warrants			$ 1,747	$ 2,554
USA [Member]
Line of Credit Facility [Abstract]
Proceeds from preference stock and warrants		$ 7,200
Repayment of debt		(3,800)
Repayment of subordinated note		$ (500)
Brazil [Member]
Line of Credit Facility [Abstract]
Percentage of revenue increase			48.00%
Percentage of targeted plant capacity			58.00%
Irgovel [Member]
Line of Credit Facility [Abstract]
Minority partner contribution amount					$ 1,700
Irgovel [Member] | Subsequent Event [Member]
Line of Credit Facility [Abstract]
Minority partner contribution amount	$ 700
Investors [Member] | Nutra SA [Member]
Noncontrolling Interest [Abstract]
Investments in variable interest entity					$ 1,100

BUSINESS (Details)

BUSINESS (Details)	3 Months Ended
	Mar. 31, 2017SegmentLocation
BUSINESS [Abstract]
Number of reportable business segments | Segment	2
Number of Locations in California	2
Number of Locations in Louisiana	1

LOSS PER SHARE (EPS) (Details)

LOSS PER SHARE (EPS) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
NUMERATOR [Abstract]
Basic and diluted - net loss attributable to RiceBran Technologies shareholders	$ (2,282)	$ 300
Dividend on preferred stock - beneficial conversion feature	(778)	(551)
Net loss attributable to RiceBran Technologies common shareholders	$ (3,060)	$ (251)
DENOMINATOR [Abstract]
Basic EPS - weighted average number of common shares outstanding (in shares)	9,657,543	9,215,684
Effect of dilutive securities outstanding (in shares)	0	0
Diluted EPS - weighted average number of shares outstanding (in shares)	9,657,543	9,215,684
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	195,273	357,386
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	17,635,102	8,712,124
Nonvested Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	256,840	867,086
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	3,054,435	835,165

REDEEMABLE NONCONTROLLING INT30

REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA (Details) $ in Thousands, BRL in Millions	3 Months Ended
	Mar. 31, 2017USD ($)RepresentativeInvestor	Mar. 31, 2017BRL	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Summary of carrying amounts included in consolidated balance sheets [Abstract]
Cash and cash equivalents	$ 3,366		$ 2,326	$ 451	$ 1,070
Other current assets (restricted $618 and $398)	896			1,213
Property and equipment, net (restricted $2,599 and $2,481)	18,881			18,933
Other noncurrent assets	141			111
Current liabilities	18,521			21,361
Current portion of long-term debt (nonrecourse)	7,435			9,878
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Investors' purchase of additional units	550		0
Irgovel [Member] | Minimum [Member]
Summary of changes for redeemable noncontrolling interest [Roll Forward]
EBITDA triggering default status | BRL		BRL 4
Nutra SA [Member]
Summary of carrying amounts included in consolidated balance sheets [Abstract]
Cash and cash equivalents	85			109
Other current assets (restricted $618 and $398)	2,174			1,696
Property and equipment, net (restricted $2,599 and $2,481)	11,052			10,889
Other noncurrent assets	1,319			1,326
Total assets	14,630			14,020
Current liabilities	8,320			8,031
Current portion of long-term debt (nonrecourse)	7,399			6,816
Total liabilities	15,719			14,847
Restricted portion of other current assets	618			398
Variable interest entity restricted portion of property, net	2,599			$ 2,481
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Redeemable noncontrolling interest in Nutra SA, beginning of period	(699)		69
Investors' interest in net loss of Nutra SA	(318)		(438)
Investors' interest in accumulated other comprehensive loss of Nutra SA	51		145
Investors' purchase of additional units	550		0
Redeemable noncontrolling interest in Nutra SA, end of period	$ (416)		$ (224)
Investors' average interest in Nutra SA during the period	35.00%	35.00%	31.70%
Investors' interest in Nutra SA at the end of the period	35.70%		32.50%
Number of representatives on management committee | Representative	3
Number of Investors on Management Committee | Investor	2
Number of representatives on management committee upon default | Representative	2
Number of Investors on Management Committee Upon Default | Investor	3
Nutra SA [Member] | Investors [Member]
Summary of changes for redeemable noncontrolling interest [Roll Forward]
Amount paid exchange for termination of rights	$ 100
Drag along right termination amount	$ 50,000

DEBT (Details)

DEBT (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total debt	$ 13,003	$ 15,887
Current portion	7,435	9,878
Long-term portion	5,568	6,009
Corporate Segment [Member]
Debt Instrument [Line Items]
Total debt	5,603	9,071
Corporate Segment [Member] | Senior Debentures, Net [Member] | Minimum [Member]
Debt Instrument [Line Items]
Average monthly adjusted EBITDA for first quarter	325
Average monthly adjusted EBITDA for second quarter	756
Average monthly adjusted EBITDA for third quarter	483
Average monthly adjusted EBITDA for fourth quarter	461
Corporate Segment [Member] | Senior Debentures, Net [Member] | Maturity Due February 2019 [Member]
Debt Instrument [Line Items]
Total debt	415	0
Aggregate principal amount	$ 6,600
Maturity date of note	Feb. 28, 2019
Effective interest rate	160.60%
Corporate Segment [Member] | Subordinated Notes, Net [Member] | Maturity Due May 2019 [Member]
Debt Instrument [Line Items]
Total debt	$ 5,094	$ 6,310
Aggregate principal amount	$ 5,900
Maturity date of note	May 31, 2019
Effective interest rate	15.00%
Variable interest rate	7.00%	11.75%
Payment of note principal	$ 200
Payment of accrued note interest	300
Corporate Segment [Member] | Other [Member]
Debt Instrument [Line Items]
Total debt	94	$ 119
Corporate Segment [Member] | Senior Revolving Loan [Member]
Debt Instrument [Line Items]
Total debt	0	1,725
Corporate Segment [Member] | Senior Term Loan, Net [Member]
Debt Instrument [Line Items]
Total debt	0	917
Brazil Segment [Member]
Debt Instrument [Line Items]
Total debt	7,400	6,816
Brazil Segment [Abstract]
Installment loan amount in arrears	700
Brazil Segment [Member] | Capital Expansion Loans [Member]
Debt Instrument [Line Items]
Total debt	2,571	2,454
Brazil Segment [Member] | Working Capital Lines of Credit [Member]
Debt Instrument [Line Items]
Total debt	702	401
Brazil Segment [Member] | Advances on Customer Export Orders [Member]
Debt Instrument [Line Items]
Total debt	1,117	1,113
Brazil Segment [Member] | Special Tax Programs [Member]
Debt Instrument [Line Items]
Total debt	2,927	2,767
Brazil Segment [Member] | Other [Member]
Debt Instrument [Line Items]
Total debt	$ 83	$ 81

EQUITY, SHARE-BASED COMPENSAT32

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Summary of Equity Activity (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period		$ (632)
Balance at beginning of period (in shares)		10,790,351
Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes		$ 269
Dividend on preferred stock - beneficial conversion feature		0
Modification of senior debenture holder warrants		582
Modification of subordinated note holder warrants		117
Change in classification of preferred stock to equity from liability		1,545
Change in classification of warrants to equity from from liability		7,851
Other		24
Accumulated deficit attributable to noncontrolling interest in Nutra SA		283
Foreign currency translation		94
Net loss		(2,282)	$ 300
Balance at end of period		$ 7,851
Balance at end of period (in shares)		10,927,204
Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period		$ 0
Modification of senior debenture holder warrants		0
Modification of subordinated note holder warrants		0
Change in classification of preferred stock to equity from liability	[1]	1,545
Change in classification of warrants to equity from from liability		0
Other		0
Accumulated deficit attributable to noncontrolling interest in Nutra SA		0
Foreign currency translation		0
Net loss		0
Balance at end of period		1,545
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period		$ 264,232
Balance at beginning of period (in shares)		10,790,351
Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes		$ 269
Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes (in shares)		108,696
Dividend on preferred stock - beneficial conversion feature		$ 778
Modification of senior debenture holder warrants		582
Modification of subordinated note holder warrants		117
Change in classification of preferred stock to equity from liability		0
Change in classification of warrants to equity from from liability		7,851
Other		$ 24
Other (in shares)		28,157
Accumulated deficit attributable to noncontrolling interest in Nutra SA		$ 0
Foreign currency translation		0
Net loss		0
Balance at end of period		$ 273,853
Balance at end of period (in shares)		10,927,204
Accumulated Deficit [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period		$ (259,819)
Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes		0
Dividend on preferred stock - beneficial conversion feature		(778)
Modification of senior debenture holder warrants		0
Modification of subordinated note holder warrants		0
Change in classification of preferred stock to equity from liability		0
Change in classification of warrants to equity from from liability		0
Other		0
Accumulated deficit attributable to noncontrolling interest in Nutra SA		0
Foreign currency translation		0
Net loss		(2,282)
Balance at end of period		(262,879)
Accumulated Deficit Attributable to Noncontrolling Interest in Nutra SA [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period		(699)
Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes		0
Dividend on preferred stock - beneficial conversion feature		0
Modification of senior debenture holder warrants		0
Modification of subordinated note holder warrants		0
Change in classification of preferred stock to equity from liability		0
Change in classification of warrants to equity from from liability		0
Other		0
Accumulated deficit attributable to noncontrolling interest in Nutra SA		283
Foreign currency translation		0
Net loss		0
Balance at end of period		(416)
Accumulated Other Comprehensive Loss [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period		(4,346)
Issuance of common stock under employee stock plans, net of shares withheld for payroll taxes		0
Dividend on preferred stock - beneficial conversion feature		0
Modification of senior debenture holder warrants		0
Modification of subordinated note holder warrants		0
Change in classification of preferred stock to equity from liability		0
Change in classification of warrants to equity from from liability		0
Other		0
Accumulated deficit attributable to noncontrolling interest in Nutra SA		0
Foreign currency translation		94
Net loss		0
Balance at end of period		$ (4,252)
[1]	Series F preferred stock, 3000 shares outstanding; Series G preferred stock, 2000 shares outstanding

EQUITY, SHARE-BASED COMPENSAT33

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrant Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Feb. 14, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 28, 2017
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 1.30
Outstanding at end of period (in dollars per share)	$ 2.17		$ 1.30
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life	3 years 9 months 18 days		6 months
Increase in authorized number of shares of common stock (in shares)	50,000,000		25,000,000		50,000,000
Former Employee [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Common stock issued for former employee (in shares)		108,696
Cash paid in lieu of bonus		$ 100,000
Board of Directors Chairman [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Transitional monthly compensation awarded	$ 8,333		$ 10,000
Transitional monthly compensation awarded in lieu of cash (in shares)	9,027		7,035
Equity Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)	6,364,110
Issued (in shares)	0
Impact of repricing debenture purchaser warrants, Prior to repricing (in shares)	(875,000)
Impact of repricing debenture purchaser warrants, After repricing (in shares)	875,000
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)	(289,669)
Impact of repricing subordinated note holder warrants, After repricing (in shares)	289,669
Impact of anti-dilution clauses, Prior to impact (in shares)	0
Impact of anti-dilution clauses, After impact (in shares)	0
Transfer from liability to equity (in shares)	14,468,163
Exercised (in shares)	0
Forfeited, expired or cancelled (in shares)	0
Outstanding at end of period (in shares)	20,832,273		6,364,110
Exercisable at end of period (in shares)	19,527,273
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 5.77
Impact of repricing debenture purchaser warrants, Prior to repricing (in dollars per share)	5.49
Impact of repricing debenture purchaser warrants, After repricing (in dollars per share)	0.96
Impact of repricing subordinated note holder warrants, Prior to repricing (in dollars per share)	5.25
Impact of repricing subordinated note holder warrants, After repricing (in dollars per share)	0.96
Transfer from liability to equity (in dollars per share)	1.16
Outstanding at end of period (in dollars per share)	2.32		$ 5.77
Exercisable at end of period (in dollars per share)	$ 2.38
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life	4 years 2 months 12 days			2 years 4 months 24 days
Impact of repricing debenture purchaser warrants, Prior to repricinng	2 years 1 month 6 days
Impact of repricing debenture purchaser warrants, After repricing	5 years 6 months
Impact of repricing subordinated note holder warrants, Prior to repricing	3 years 3 months 18 days
Impact of repricing subordinated note holder warrants, After pricing	3 years 3 months 18 days
Transfer from liability to equity	4 years 9 months 14 days
Exercisable, weighted average remaining contractual life	4 years 1 month 6 days
Liability Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)	4,474,868
Issued (in shares)	11,783,163
Impact of repricing debenture purchaser warrants, Prior to repricing (in shares)	0
Impact of repricing debenture purchaser warrants, After repricing (in shares)	0
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)	0
Impact of repricing subordinated note holder warrants, After repricing (in shares)	0
Impact of anti-dilution clauses, Prior to impact (in shares)	(1,489,868)
Impact of anti-dilution clauses, After impact (in shares)	2,327,919
Transfer from liability to equity (in shares)	(14,468,163)
Exercised (in shares)	0
Forfeited, expired or cancelled (in shares)	0
Outstanding at end of period (in shares)	2,627,919		4,474,868
Exercisable at end of period (in shares)	2,627,919
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 1.82
Issued (in dollars per share)	0.96
Impact of anti-dilution clauses, Prior to impact (in dollars per share)	1.50
Impact of anti-dilution clauses, After impact (in dollars per share)	0.96
Transfer from liability to equity (in dollars per share)	1.16
Outstanding at end of period (in dollars per share)	1.03		$ 1.82
Exercisable at end of period (in dollars per share)	$ 1.03
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life	10 months 24 days			3 years 3 months 18 days
Issued	5 years
Impact of anti-dilution clauses, Prior to impact	9 months 18 days
Impact of anti-dilution clauses, After impact	9 months 18 days
Transfer from liability to equity	4 years 9 months 14 days
Exercisable, weighted average remaining contractual life	10 months 24 days
Series F Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred Stock, Shares Outstanding	3,000
Series G Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred Stock, Shares Outstanding	2,000

EQUITY, SHARE-BASED COMPENSAT34

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Details)	Feb. 28, 2017USD ($)$ / sharesshares	Feb. 09, 2017USD ($)$ / sharesshares	Feb. 08, 2017USD ($)$ / sharesshares	Apr. 30, 2017Installment$ / sharesshares	Mar. 31, 2017$ / sharesshares	Mar. 31, 2017USD ($)shares	Mar. 31, 2016USD ($)	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares					23,460,192	23,460,192		10,838,978
Exercise price per warrant (in dollars per share) | $ / shares								$ 1.50
Debt conversion amount						$ 138,000	$ 0
Loss on extinguishment of debt						(1,680,000)	0
Proceeds from issuance of debt and warrants, net of issuance costs						5,518,000	300,000
Interest expense debt						542,000	292,000
Repayment of debt						$ 8,644,000	$ 10,329,000
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares	2,327,919							1,489,868
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96
Warrants [Member] | Expiration February, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares	1,423,488
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96
Series F Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock issued (in shares) | shares					3,000	3,000
Series G Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock issued (in shares) | shares					2,000	2,000
Preferred shares converted into common stock (in shares) | shares					1,897,983	1,897,983
Preferred stock conversion ratio to common stock						948.9915
Preferred stock, dividend						$ 1,000
Debt conversion amount						$ 100,000
Debt conversion, stock (in shares) | shares						180
Net proceeds from the exchange of subordinated notes						$ 1,700,000
Cash offering expenses						100,000
Proceeds allocated to derivative warrant liability						1,000,000
Warrants recorded at fair value						100,000
Loss on extinguishment of debt						(100,000)
Decrease in subordinated debt						(100,000)
Proceed recorded as preferred stock						1,200,000
Recorded dividend for preferred stock						$ 800,000
Subordinated Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares	3,484,675
Exercise price per warrant (in dollars per share) | $ / shares	$ 0.96
Loss on extinguishment of debt			$ (1,500,000)
Decrease in subordinated debt			(900,000)
Fair value of derivative warrant liabilities	$ 2,300,000
Fair value increase in common stock	$ 100,000
Annual interest rate	7.00%							11.75%
Repayment of debt			$ 500,000
Subordinated Debt [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares			$ 0.96					$ 5.25
Amendment of existing warrants (in shares) | shares			289,669
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares					100,000
Granted exercise price (in dollars per share) | $ / shares					$ 0.76
Vested in August 2017 (in shares) | shares					25,000
Executive Officer and Employees [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares				345,500
Granted exercise price (in dollars per share) | $ / shares				$ 0.85
Number of equal annual installments | Installment				4
Senior Secured Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of debt and warrants, net of issuance costs		$ 5,500,000
Placement fees and allocation expenses		$ 500,000
Warrants exercisable term								2 years 1 month 6 days
Senior Secured Debt [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares) | shares		6,875,000
Exercise price per warrant (in dollars per share) | $ / shares		$ 0.96
Aggregate subscription amount		$ 6,000,000
Aggregate principal amount		$ 6,600,000
Amendment of existing warrants (in shares) | shares		875,000
Exercise price per warrant one (in dollars per share) | $ / shares		$ 5.49
Warrants exercisable term		5 years 6 months
Fair value of derivative warrant liabilities		$ 4,600,000
Fair value increase in common stock		500,000
Debt Issuance Cost		400,000
Extinguishment of term loan		3,800,000
Repayment of subordinated note		200,000
Interest expense debt		$ 300,000

EQUITY AND SHARE-BASED COMPENSA

EQUITY AND SHARE-BASED COMPENSATION, Warrants Outstanding (Details) - $ / shares		1 Months Ended	3 Months Ended	12 Months Ended
		Mar. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Summary of information related to outstanding and exercisable warrants [Abstract]
Weighted average exercise price (in dollars per share)		$ 2.17	$ 2.17	$ 1.30
Shares under warrants, outstanding (in shares)		23,460,192	23,460,192	10,838,978
Weighted average remaining contractual life			3 years 9 months 18 days	6 months
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Common stock issued (in shares)		1,175,000
Increase in common shares authorized (in shares)		1,700,000
Number of trading days			65 days
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member] | Vesting Price Equals or Exceeds $5.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Vesting percentage			10.00%
Vesting price (in dollars per share)			$ 5
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member] | Vesting Price Equals or Exceeds $10.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Vesting percentage			30.00%
Vesting price (in dollars per share)			$ 10
Equity Incentive Plan 2014 [Member] | Restricted Stock Award [Member] | Vesting Price Equals or Exceeds $15.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Vesting percentage			60.00%
Vesting price (in dollars per share)			$ 15
Equity Warrants [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Weighted average exercise price (in dollars per share)		$ 2.32	$ 2.32	$ 5.77
Weighted average remaining contractual life			4 years 2 months 12 days		2 years 4 months 24 days
Equity Warrants [Member] | $0.96 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)			$ 0.96
Weighted average exercise price (in dollars per share)		$ 0.96	$ 0.96	$ 0
Shares under warrants, outstanding (in shares)		12,947,832	12,947,832	0
Weighted average remaining contractual life			3 years 1 month 6 days	0 years
Equity Warrants [Member] | $2.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)			$ 2
Weighted average exercise price (in dollars per share)		$ 2	$ 2	$ 0
Shares under warrants, outstanding (in shares)		2,660,000	2,660,000	0
Weighted average remaining contractual life			4 years 2 months 12 days	0 years
Equity Warrants [Member] | $5.25 to $5.87 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)			$ 5.25
Exercise price range, upper range limit (in dollars per share)			5.87
Weighted average exercise price (in dollars per share)		$ 5.33	$ 5.33	$ 5.36
Shares under warrants, outstanding (in shares)		3,156,670	3,156,670	4,296,339
Weighted average remaining contractual life			2 years 6 months	2 years 8 months 12 days
Equity Warrants [Member] | $6.55 to $16.80 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)			$ 6.55
Exercise price range, upper range limit (in dollars per share)			16.80
Weighted average exercise price (in dollars per share)		$ 6.61	$ 6.61	$ 6.61
Shares under warrants, outstanding (in shares)		2,067,771	2,067,771	2,067,771
Weighted average remaining contractual life			1 year 8 months 12 days	2 years
Liability Warrants [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Weighted average exercise price (in dollars per share)		$ 1.03	$ 1.03	$ 1.82
Weighted average remaining contractual life			10 months 24 days		3 years 3 months 18 days
Liability Warrants [Member] | $0.96 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[1]		$ 0.96
Weighted average exercise price (in dollars per share)	[1]	$ 0.96	$ 0.96	$ 0
Shares under warrants, outstanding (in shares)	[1]	2,327,919	2,327,919	0
Weighted average remaining contractual life	[1]		8 months 12 days	0 years
Liability Warrants [Member] | $1.50 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[2]		$ 1.50
Weighted average exercise price (in dollars per share)	[2]	$ 1.60	$ 1.60	$ 0
Shares under warrants, outstanding (in shares)	[2]	300,000	300,000	0
Weighted average remaining contractual life	[2]		3 years 1 month 6 days	0 years
Liability Warrants [Member] | $1.50 to $1.60 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)	[1],[2]		$ 1.50
Exercise price range, upper range limit (in dollars per share)	[1],[2]		1.60
Weighted average exercise price (in dollars per share)	[1],[2]	$ 0	$ 0	$ 1.52
Shares under warrants, outstanding (in shares)	[1],[2]	0	0	1,789,868
Weighted average remaining contractual life	[1],[2]		0 years	1 year 3 months 18 days
Liability Warrants [Member] | $2.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[3]		$ 2
Weighted average exercise price (in dollars per share)	[3]	$ 0	$ 0	$ 2
Shares under warrants, outstanding (in shares)	[3]	0	0	2,660,000
Weighted average remaining contractual life	[3]		0 years	4 years 7 months 6 days
Liability Warrants [Member] | $5.25 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[3]		$ 5.25
Weighted average exercise price (in dollars per share)	[3]	$ 0	$ 0	$ 5.25
Shares under warrants, outstanding (in shares)	[3]	0	0	25,000
Weighted average remaining contractual life	[3]		0 years	3 years 7 months 6 days
[1]	Includes two warrants which contain full ratchet anti-dilution provisions and are classified as derivative warrant liabilities in our balance sheets. Under the anti-dilution clauses contained in these warrants, in the event of equity issuances (i.e. issuances of our common stock, certain awards of stock options to employees, and issuances of warrants and/or other convertible instruments) at prices below the exercise prices of these warrants, we are required to lower the exercise price on these warrants and increase the number of shares underlying these warrants.
[2]	Includes a warrant for the purchase of 300,000 shares of our common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event of issuances of stock options and/or convertible instruments with anti-dilution provisions (providing for the adjustment of the exercise price, conversion price or other price or rate at which shares of common stock thereunder may be purchased, acquired or converted, and/or any upward adjustment in the number of shares of common stock issuable) we may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant.
[3]	The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017.

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of debt	$ 13,003	$ 15,887
Corporate Segment [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	4,500
Carrying value of debt	5,603	9,071
Brazil [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of debt	7,400	6,816
Derivative Warrant Liabilities [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ (494)	$ (1,527)
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	0.80%
Expected volatility	80.00%	64.00%
Derivative Warrant Liabilities [Member] | Recurring [Member] | Minimum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate		0.60%
Derivative Warrant Liabilities [Member] | Recurring [Member] | Maximum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate		1.90%
Derivative Warrant Liabilities [Member] | Recurring [Member] | Weighted Average [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	0.80%	1.60%
Expected volatility	80.00%	64.00%
Derivative Warrant Liabilities [Member] | Level 1 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 0	$ 0
Derivative Warrant Liabilities [Member] | Level 2 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	0	0
Derivative Warrant Liabilities [Member] | Level 3 [Member] | Recurring [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ (494)	$ (1,527)

FAIR VALUE MEASUREMENTS, Unobse

FAIR VALUE MEASUREMENTS, Unobservable Input Reconciliation (Details) - Recurring [Member] - Derivative Warrant Liabilities [Member] - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Changes in level 3 items measured at fair value on a recurring basis [Roll Forward]
Fair Value as of Beginning of Period		$ (1,527)	$ (678)
Total Realized and Unrealized Gains (Losses)	[1]	1,099	811
Issuance of New Instruments		(7,917)	(2,473)
Reclassify to (Deficit) Equity		7,851	0
Fair Value, at End of Period		$ (494)	$ (2,340)
[1]	Included in change in fair value of derivative warrant liabilities in our unaudited condensed consolidated statements of operations.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - 3 months ended Mar. 31, 2017 - Irgovel [Member] BRL in Millions, $ in Millions	BRL	USD ($)
Loss Contingencies [Line Items]
Damages sought by plaintiff | $		$ 0.9
Minimum [Member]
Irgovel - Events of Default [Abstract]
EBITDA triggering default status | BRL	BRL 4

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Related Party Transaction [Line Items]
Interest paid	$ 672	$ 492
Halpern [Member]
Related Party Transaction [Line Items]
Percentage of outstanding debt retained by related party	43.00%
Halpern [Member] | Subordinated Notes [Member]
Related Party Transaction [Line Items]
Interest paid	$ 100	$ 200

FAILURE TO COMPLY WITH NASDAQ40

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 10, 2017	Dec. 31, 2016	Aug. 18, 2016	Jun. 30, 2016
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
Nasdaq minimum stockholders' equity listing requirement				$ 2,500
Stockholders' equity (deficit)	$ 7,851		$ (632)		$ (36)
Nasdaq grant of extension period to regain compliance under minimum stockholders' equity requirement	180 days
Nasdaq minimum bid price requirement (in dollars per share)		$ 1
Number of consecutive business days under minimum bid requirement	10 days
Nasdaq grant of extension period to regain compliance under minimum bid requirement	180 days

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	$ 11,435	$ 10,051
Cost of goods sold	8,924	7,814
Gross profit	2,511	2,237
Depreciation and amortization (in selling, general and administrative)	(114)	(348)
Other operating expense	(2,913)	(3,379)
Loss from operations	(516)	(1,490)
Net income (loss) attributable to RiceBran Technologies shareholders	(2,282)	300
Interest expense	1,406	1,091
Depreciation (in costs of goods sold)	469	373
Purchases of property	132	208
Segment information for selected balance sheet accounts [Abstract]
Inventories	4,028		$ 3,773
Property and equipment, net	18,881		18,933
Goodwill	790		790
Intangible assets, net	206		242
Total assets	32,463		28,845
Corporate [Member]
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	0	0
Cost of goods sold	0	0
Gross profit	0	0
Depreciation and amortization (in selling, general and administrative)	(16)	(23)
Other operating expense	(1,375)	(1,274)
Loss from operations	(1,391)	(1,297)
Net income (loss) attributable to RiceBran Technologies shareholders	(3,124)	433
Interest expense	1,057	679
Depreciation (in costs of goods sold)	0	0
Purchases of property	0	0
Segment information for selected balance sheet accounts [Abstract]
Inventories	0		0
Property and equipment, net	378		392
Goodwill	0		0
Intangible assets, net	0		0
Total assets	3,873		1,339
Operating Segments [Member] | USA [Member]
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	8,032	7,754
Cost of goods sold	5,449	5,294
Gross profit	2,583	2,460
Depreciation and amortization (in selling, general and administrative)	(82)	(314)
Other operating expense	(1,020)	(1,375)
Loss from operations	1,481	771
Net income (loss) attributable to RiceBran Technologies shareholders	1,481	771
Interest expense	0	0
Depreciation (in costs of goods sold)	204	179
Purchases of property	53	65
Segment information for selected balance sheet accounts [Abstract]
Inventories	2,850		2,848
Property and equipment, net	7,451		7,652
Goodwill	790		790
Intangible assets, net	206		242
Total assets	13,960		13,486
Operating Segments [Member] | Brazil [Member]
Segment information identified and reconciliations of segment information to total consolidated information [Abstract]
Revenues	3,403	2,297
Cost of goods sold	3,475	2,520
Gross profit	(72)	(223)
Depreciation and amortization (in selling, general and administrative)	(16)	(11)
Other operating expense	(518)	(730)
Loss from operations	(606)	(964)
Net income (loss) attributable to RiceBran Technologies shareholders	(639)	(904)
Interest expense	349	412
Depreciation (in costs of goods sold)	265	194
Purchases of property	79	$ 143
Segment information for selected balance sheet accounts [Abstract]
Inventories	1,178		925
Property and equipment, net	11,052		10,889
Goodwill	0		0
Intangible assets, net	0		0
Total assets	$ 14,630		$ 14,020

SEGMENT INFORMATION, Revenue by

SEGMENT INFORMATION, Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 11,435	$ 10,051
Reportable Geographic Segment [Member] | United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	6,927	7,029
Reportable Geographic Segment [Member] | Brazil [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	2,918	2,087
Reportable Geographic Segment [Member] | Other International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 1,590	$ 935